Skip to main content

Table 6 Associations between NEDD4–1 and NRDP1 protein expression and clinicopathological characteristics in HER2-amplified breast cancer cohort

From: Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

Characteristic   Cytoplasmic NRDP1 expression n (%) Nuclear NRDP1 expression n (%) Cellular NEDD4–1 expression n (%)
n NRDP1- NRDP1+ p NRDP1- NRDP1+ p NEDD4–1- NEDD4–1+ p
Cases 145 133 (91.7) 12 (8.3)   133 (91.7) 12 (8.3)   25 (17.2) 120 (82.8)  
Estrogen receptor     0.057    0.206    0.421
 Positive 97 86 (64.7) 11 (91.7)   87 (65.4) 10 (83.3)   15 (60.0) 82 (68.3)  
 Negative 48 47 (35.3) 1 (8.3)   46 (34.6) 2 (16.7)   10 (40.0) 38 (31.7)  
Progesterone receptor     0.006**    0.125    0.053
 Positive 66 56 (42.1) 10 (83.3)   58 (43.6) 8 (66.7)   7 (28.0) 59 (49.2)  
 Negative 79 77 (57.9) 2 (16.7)   75 (56.4) 4 (33.3)   18 (72.0) 61 (50.8)  
Histological grade     0.953    0.446    0.134
 I-II 35 32 (24.2) 3 (25.0)   31 (23.5) 4 (33.3)   9 (36.0) 26 (21.8)  
 III 109 100 (75.8) 9 (75.0)   101 (76.5) 8 (66.7)   16 (64.0) 93 (78.2)  
Ki-67 proliferation index     0.228    0.228    1.000
 Low 29 25 (18.8) 4 (33.3)   25 (18.8) 4 (33.3)   5 (25.0) 24 (20.0)  
 High 116 108 (81.2) 8 (66.7)   108 (81.2) 8 (66.7)   20 (75.0) 96 (80.0)  
Histological type     0.022*    0.880    0.403
 Ductal 128 119 (93.7) 9 (75.0)   118 (92.2) 10 (90.9)   22 (88.0) 106 (93.0)  
 Lobular 11 8 (6.3) 3 (25.0)   10 (7.8) 1 (9.1)   3 (12.0) 8 (7.0)  
Lymph nodal status     0.120    0.277    0.516
 Positive pN+ 60 58 (45.3) 2 (20.0)   53 (42.1) 7 (58.3)   9 (37.5) 51 (44.7)  
 Negative pN0 78 70 (54.7) 8 (80.0)   73 (57.9) 5 (41.7)   15 (62.5) 63 (55.3)  
Tumor size (cm)     0.669    0.820    0.715
 < 2 cm 57 52 (48.1) 5 (55.6)   52 (49.1) 5 (45.5)   9 (45.0) 48 (49.5)  
 ≥ 2 cm 60 56 (51.9) 4 (44.4)   54 (50.9) 6 (54.5)   11 (55.0) 49 (50.5)  
Tumor size (TNM stage)     0.511    0.341    0.177
  pT1-pT2 138 127 (96.2) 11 (100.0)   127 (96.9) 11 (91.7)   23 (92.0) 115 (97.5)  
 pT3-pT4 5 5 (3.8) 0 (0.0)   4 (3.1) 1 (8.3)   2 (8.0) 3 (2.5)  
Patient age at diagnosis     0.856    0.004**    0.771
 < 50 years 27 25 (18.8) 2 (16.7)   21 (15.8) 6 (50.0)   4 (16.0) 23 (19.2)  
 ≥ 50 years 118 108 (81.2) 10 (83.3)   112 (84.2) 6 (50.0)   21 (84.0) 97 (80.8)  
HER3 membrane expression     0.905    0.505    0.002**
 Low 26 24 (18.0) 2 (16.7)   23 (17.3) 3 (25.0)   10 (40.0) 16 (13.3)  
 High 119 109 (82.0) 10 (83.3)   110 (82.7) 9 (75.0)   15 (60.0) 104 (86.7)  
HER3 cytoplasmic expression     0.300    0.215    0.360
 Low 11 11 (8.3) 0 (0.0)   9 (6.8) 2 (16.7)   3 (12.0) 8 (6.7)  
 High 134 122 (91.7) 12 (100.0)   124 (93.2) 10 (83.3)   22 (88.0) 112 (93.3)  
HER3 total cellular expression     0.041*    0.942    0.620
 Low 35 35 (26.3) 0 (0.0)   32 (24.1) 3 (25.0)   7 (28.0) 28 (23.3)  
 High 110 98 (73.7) 12 (100.0)   101 (75.9) 9 (75.0)   18 (72.0) 92 (76.7)  
Cytokeratin 5/14 expression     0.199    0.199    0.578
 Negative 127 115 (87.8) 12 (100.0)   115 (87.8) 12 (100.0)   23 (92.0) 104 (88.1)  
 Positive 16 16 (12.2) 0 (0.0)   16 (12.2) 0 (0.0)   2 (8.0) 14 (11.9)  
  1. p-values were calculated using Pearson’s Chi-Square test, statistically significant values are underlined and marked with *p<0.05, **p≤0.01, and ***p≤0.001